Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 6/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9498944 | 0.90 | TTR (0.61) | CA2TTRAPEX1NSD2 | |
| SCHEMBL9177053 | 0.81 | TTR (0.46) | CA2TTRAPEX1HDAC3IDO1 | |
| SCHEMBL16097559 | 0.79 | ALOX5AP (0.41) | CA2TTRAPEX1NSD2 | |
| SCHEMBL1694943 | 0.79 | APEX1 (0.45) | CA2TTRAPEX1NSD2AURKA | |
| SCHEMBL292555 | 0.79 | APEX1 (0.45) | CA2TTRAPEX1HDAC3IDO1 | |
| SCHEMBL1282672 | 0.79 | APEX1 (0.42) | CA2TTRAPEX1HDAC3IDO1 | |
| SCHEMBL635315 | 0.78 | CA2 (0.57) | CA2TTRAPEX1 | |
| SCHEMBL6867446 | 0.77 | APEX1 (0.55) | TTRAPEX1HDAC3NSD2 | |
| SCHEMBL5595987 | 0.77 | APEX1 (0.41) | CA2TTRAPEX1HDAC3IDO1 | |
| SCHEMBL28718534 | 0.77 | TTR (0.45) | TTRAPEX1HDAC3IDO1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1114186-B1 | METHOD FOR CONTROLLING QUALITY IN THE CONSTRUCTION OF OLIGOMER GRIDS | DEUTSCHES KREBSFORSCH (DE) | 2006-07-05 | — | — | EP | disclosed |
| US-20030175781-A1 | Method for controlling quality in the construction of oligomer arrays | BEIER MARKUS (DE) | 2003-09-18 | — | — | US | disclosed |
| US-6582917-B1 | Generation of preferential oligonucleotides; obtain oligomers, fuse to labeled phosphates, detect signal, monitor properties of oligonucleotides | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2003-06-24 | — | — | US | disclosed |
| EP-1114186-A2 | METHOD FOR CONTROLLING QUALITY IN THE CONSTRUCTION OF OLIGOMER GRIDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-07-11 | — | — | EP | disclosed |
| US-6048975-A | USE OF DANSYLETHOXYCARBONYL GROUP AS BASE-LABILE 5'-HYDROXYL PROTECTIVE GROUP; EASE OF DETECTION AND EASE OF ELIMINATION WITH BY-PRODUCT INHIBITION FOR HIGH YIELD SYNTHESIS IN VERY SMALL QUANTITIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-04-11 | — | — | US | disclosed |
| WO-2000015837-A2 | METHOD FOR CONTROLLING QUALITY IN THE CONSTRUCTION OF OLIGOMER GRIDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2000-03-23 | — | — | WO | disclosed |
| US-5945524-A | NUCLEOSIDE WITH DANSYLETHOXYCARBONYL GROUP AS BASE-LABILE 5'-HYDROXYL PROTECTIVE GROUP; FOR EFFICIENT SYNTHESIS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | disclosed |
| US-5631362-A | FORMING DNA AND RNA BY POLYCONDENSATION OF MONONUCLEOTIDES WITH PROTECTIVE SULFONYLALKYL DIMETHYLAMINONAPHTHALENE GROUPS FOR ALKOXY FURAN GROUPS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| EP-0475443-B1 | Chemical synthesis of oligonucleotides | HOECHST AG (DE) | 1994-10-19 | — | — | EP | disclosed |
| EP-0475443-A2 | Chemical synthesis of oligonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-03-18 | — | — | EP | disclosed |
| US-4745187-A | Process for the preparation of water-soluble phthalocyanine dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030175781-A1 | Method for controlling quality in the construction of oligomer arrays | PHAX, MYCBP, RNGTT | CA2 3262/4885TTR 537/4885APEX1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.